Clinical trial · Interventional
Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection
Efficacy of Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection: A Randomized Controlled Trial
NCT05082441CI-TRIAL-00054524unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Liposomal bupivacaine (Exparel) has been used as an adjunct to pain management in the perioperative setting. However, the efficacy of the drug has not bewen studied in patients with benign soft tissue tumor resections. The goal of the study is to see if Exparel controls pain and improves functional outcomes for patients after these procedures compared to the current standard Bupivacaine HCL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Neoplasm | Benign Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacaine Hydrochloride | Drug | — | UNRESOLVED |
| Liposomal bupivacaine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- experimental
- description
- Exparel group
- interventionNames
- Drug: Liposomal bupivacaine
- type
- ACTIVE_COMPARATOR
- label
- control
- description
- plain bupivacaine
- interventionNames
- Drug: Bupivacaine Hydrochloride
Primary outcomes (1)
- measure
- Opioid Use
- timeFrame
- first 7 days postoperatively
- description
- Amount of morphine equivalents used for postoperative pain control
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All benign soft tissue tumors greater than one cubic cm * Adults 18 years and older Exclusion Criteria: * Pregnant females * Women who are breastfeeding * Less than 18 years old * Malignant tumors * Tumors smaller than 1 cubic cm * Allergy to Exparel * Patients who are opioid dependent defined as patients on a long acting narcotic or who take more than 30 morphine equivalents per day * Allergy to amide anesthetics * bone tumors * Patients unable to comply with the study standards and follow up
References
Publications (0)
Data not yet available
No reference posted for this study.